Thiazovivin: A High-Purity ROCK Inhibitor for Enhanced Cell Reprogramming

Executive Summary: Thiazovivin (CAS No. 1226056-71-8) is a small molecule inhibitor of Rho-associated protein kinase (ROCK) with a molecular weight of 311.36, and a purity of at least 98% as supplied by APExBIO (product page). It markedly increases the efficiency of fibroblast reprogramming to induced pluripotent stem cells (iPSCs) when combined with SB 431542 and PD 0325901, and enhances survival of human embryonic stem cells (hESCs) post-trypsinization—critical for robust stem cell workflows (Xie et al., 2021). Thiazovivin is soluble to at least 15.55 mg/mL in DMSO and must be stored at -20°C for stability. Its mechanism is well-established: inhibition of the ROCK signaling pathway reduces actomyosin contractility, thereby promoting cell survival and plasticity (related article). These attributes have made Thiazovivin a standard for reproducible, high-efficiency cell reprogramming and survival assays in stem cell research and regenerative medicine.

Biological Rationale

The ROCK signaling pathway is a pivotal regulator of cytoskeletal dynamics, cell plasticity, and apoptosis. Inhibition of ROCK has been shown to promote cell survival and facilitate dedifferentiation—key steps in generating induced pluripotent stem cells (iPSCs) and maintaining human embryonic stem cells (hESCs) in culture (Xie et al., 2021). Cellular plasticity, governed by signaling and epigenetic mechanisms, is integral to developmental biology and regenerative medicine. Thiazovivin, as a selective ROCK inhibitor, directly modulates these processes. In practical terms, it addresses the challenge of low cell viability during cell passaging and reprogramming, which historically limited the scalability and reproducibility of stem cell workflows (scenario-driven guide; this article provides updated benchmarks and workflow parameters for Thiazovivin use beyond those resources).

Mechanism of Action of Thiazovivin

Thiazovivin, chemically known as N-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide, inhibits ROCK1 and ROCK2 kinases at low micromolar concentrations. This inhibition disrupts downstream phosphorylation of myosin light chain and other cytoskeletal targets, reducing actomyosin contractility. The decrease in contractility attenuates anoikis (detachment-induced apoptosis), thereby improving cell survival after dissociation (Xie et al., 2021). In fibroblast reprogramming, Thiazovivin synergizes with TGF-β inhibitors (SB 431542) and MEK inhibitors (PD 0325901) to increase reprogramming efficiency by more than 50% relative to controls under defined, feeder-free conditions. This action is highly specific and dose-dependent, with optimal concentrations typically between 2–10 μM for in vitro applications (mechanistic analysis; our review incorporates recent stability and storage recommendations).

Evidence & Benchmarks

• Thiazovivin at 2 μM increases hESC survival rates post-trypsinization by 3–5 fold compared to untreated controls (Xie et al., 2021, DOI).
• Combined use of Thiazovivin, SB 431542, and PD 0325901 enhances fibroblast-to-iPSC conversion rates up to 200% under feeder-free, serum-free conditions (Xie et al., 2021, DOI).
• Thiazovivin demonstrates solubility of at least 15.55 mg/mL in DMSO at room temperature, supporting concentrated stock preparation (APExBIO).
• Purity of ≥98% ensures batch-to-batch reproducibility in stem cell research workflows (APExBIO).
• Stability is optimal at -20°C, with solutions not recommended for storage beyond 2–3 weeks in DMSO (APExBIO).

This article extends the mechanistic coverage of previous resources by integrating quantitative benchmarks for storage, purity, and workflow reproducibility.

Applications, Limits & Misconceptions

Thiazovivin is routinely used in:

• Enhancing survival of hESCs and iPSCs during single-cell dissociation and passaging.
• Increasing efficiency and reproducibility of fibroblast reprogramming protocols.
• Facilitating high-throughput screening in cell fate engineering applications.

These applications are well documented in both peer-reviewed literature and product validation studies (APExBIO; thought-leadership article: this article provides updated storage and solubility parameters).

Common Pitfalls or Misconceptions

• Thiazovivin does not induce pluripotency by itself; it must be combined with transcription factors or other small molecules.
• Excessive concentrations (>20 μM) may induce cytotoxicity in some cell types.
• It is not a pan-cytoprotective agent and does not rescue all forms of cell death (e.g., necrosis unrelated to ROCK signaling).
• Long-term storage of solutions, even at -20°C, may lead to degradation; use freshly prepared solutions when possible.
• Thiazovivin’s efficacy is highly context-dependent; results may not generalize across non-mammalian or non-stem cell lines.

Workflow Integration & Parameters

Thiazovivin (SKU A5506) is typically supplied as a solid with ≥98% purity by APExBIO and should be dissolved in DMSO to prepare stock solutions (solubility: ≥15.55 mg/mL). Stocks are stable for up to 3 months at -20°C in tightly sealed vials. For cell culture, a working concentration of 2–10 μM is recommended, added immediately after cell dissociation.

For reprogramming workflows, Thiazovivin is used in conjunction with TGF-β and MEK inhibitors to maximize iPSC yield and colony integrity. It is compatible with feeder-free, serum-free systems. For optimal reproducibility, thaw working aliquots immediately before use and avoid repeated freeze-thaw cycles.

This guidance clarifies and extends protocol recommendations in Thiazovivin (SKU A5506): Solving Reproducibility in Stem ..., which focuses primarily on real-world troubleshooting; here, we provide a consolidated parameter set for standardized use.

Conclusion & Outlook

Thiazovivin is a well-validated, high-purity ROCK inhibitor that has transformed cell survival and reprogramming protocols in stem cell research. Its defined mechanism, robust solubility, and reproducibility make it an essential reagent for cell fate engineering and regenerative medicine. Ongoing research is exploring its role in combination therapies and in modulating cellular plasticity in cancer and developmental models (Xie et al., 2021). For detailed specifications and ordering, refer to the official APExBIO Thiazovivin product page.